Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
To own Oscar Health, you need to believe its technology centric ACA model can translate growing membership and revenue into sustainable profitability, while managing medical costs and regulation. The latest attention on its tech platform, share price strength, and upcoming Q2 2026 results mainly reinforces that the key near term catalyst remains proof of consistent operating profits. The biggest risk is that high volatility and ongoing losses persist, and this news does not materially change that.
The most relevant announcement here is Oscar’s scheduled Q2 2026 earnings release and conference call on August 6. With the stock near all time highs and expectations already built around an eventual shift to profitability, this update will be closely watched for progress on margins, medical loss ratios, and any commentary on the tech enabled cost structure that underpins the investment case.
Yet behind the tech story, investors should be aware of how rising medical costs and regulatory shifts could still...
Read the full narrative on Oscar Health (it's free!)
Oscar Health's narrative projects $23.1 billion revenue and $981.1 million earnings by 2029. This requires 20.1% yearly revenue growth and a $1,020.5 million earnings increase from -$39.4 million today.
Uncover how Oscar Health's forecasts yield a $22.60 fair value, a 27% downside to its current price.
Before this news, the most optimistic analysts were projecting Oscar’s revenue to reach about US$25.5 billion and earnings of roughly US$1.1 billion by 2029, which is far more bullish than consensus. If you are weighing these upside projections against concerns about high medical loss ratios and ACA policy risk, this latest focus on Oscar’s tech platform and upcoming earnings could eventually push expectations in either direction, so it is worth comparing how your view lines up with both narratives.
Explore 14 other fair value estimates on Oscar Health - why the stock might be worth as much as 46% more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com